1. 32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers. (April 2019) Authors: Litzenburger, Tobias; Müller, Fabian; Schultz, Armin; Klein, Elliott; Ramanujam, Meera; Wu, Jing; Wiebe, Sabrina; Benediktus, Ewald; Hui, Jianan; Li, Xiujiang; Flack, Mary; Padula, Steven J; Visvanathan, Sudha; Steffgen, Jürgen; Hünnemeyer, Andreas Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Issue 6 (22nd June 2019) Authors: Visvanathan, Sudha; Daniluk, Stefan; Ptaszyński, Rafał; Müller-Ladner, Ulf; Ramanujam, Meera; Rosenstock, Bernd; Eleftheraki, Anastasia G; Vinisko, Richard; Petříková, Alena; Kellner, Herbert; Dokoupilova, Eva; Kwiatkowska, Brygida; Alten, Rieke; Schwabe, Christian; Baum, Patrick; Joseph, David; ... Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 6(2019) Page Start: 754 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Issue 6 (22nd March 2019) Authors: Visvanathan, Sudha; Daniluk, Stefan; Ptaszyński, Rafał; Müller-Ladner, Ulf; Ramanujam, Meera; Rosenstock, Bernd; Eleftheraki, Anastasia G; Vinisko, Richard; Petříková, Alena; Kellner, Herbert; Dokoupilova, Eva; Kwiatkowska, Brygida; Alten, Rieke; Schwabe, Christian; Baum, Patrick; Joseph, David; ... Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 6(2019) Page Start: 754 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Issue 10080 (29th April 2017) Authors: Feagan, Brian G; Sandborn, William J; D'Haens, Geert; Panés, Julián; Kaser, Arthur; Ferrante, Marc; Louis, Edouard; Franchimont, Denis; Dewit, Olivier; Seidler, Ursula; Kim, Kyung-Jo; Neurath, Markus F; Schreiber, Stefan; Scholl, Paul; Pamulapati, Chandrasena; Lalovic, Bojan; Visvanathan, Sudha; ... Journal: Lancet Issue: Volume 389:Issue 10080(2017) Page Start: 1699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. (October 2018) Authors: Feagan, Brian G; Panés, Julián; Ferrante, Marc; Kaser, Arthur; D'Haens, Geert R; Sandborn, William J; Louis, Edouard; Neurath, Markus F; Franchimont, Denis; Dewit, Olivier; Seidler, Ursula; Kim, Kyung-Jo; Selinger, Christian; Padula, Steven J; Herichova, Ivona; Robinson, Anne M; Wallace, Kori; Zh... Journal: Lancet gastroenterology and hepatology Issue: Volume 3:Number 10(2018) Page Start: 671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Issue 9 (26th June 2018) Authors: Baeten, Dominique; Østergaard, Mikkel; Wei, James Cheng-Chung; Sieper, Joachim; Järvinen, Pentti; Tam, Lai-Shan; Salvarani, Carlo; Kim, Tae-Hwan; Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; Hall, David B; Aslanyan, Stella; Scholl, Paul; Padula, Steven J Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 9(2018) Page Start: 1295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. (19th July 2018) Authors: Visvanathan, Sudha; Baum, Patrick; Salas, Azucena; Vinisko, Richard; Schmid, Ramona; Grebe, Kristie M; Davis, Justin W; Wallace, Kori; Böcher, Wulf O; Padula, Steven J; Fine, Jay S; Panés, Julián Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 10(2018:Oct.) Page Start: 1170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗